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kappa beta (NFκβ) activation regulates chondrogenic differentia-
tion. This study aims to elucidate the role of NFκβ and downstream
inﬂammatory mediators during the early phase of chondrogenesis.
Methods: The chondroprogenitor ATDC5 was differentiated in
presence of NFκβ activating agents LPS and TNFα or with
the NFκβ inhibitors TLCK, sulfasalazine or parthenolide. NFκβ
activation was determined by analyzing nuclear translocation
and expression of NFκβ targets by RT-qPCR and westernblot.
Prostaglandin E2 (PGE2) production in medium was measured
using a speciﬁc ELISA. Cartilage speciﬁc markers were analyzed
by RT-qPCR and western blot. Similar experiments were per-
formed with human bone marrow stem cells (hBMSCs). hBMSCs
were obtained from iliac crest bone marrow aspirate from 5 young,
genetically healthy, individuals.
Results: ATDC5 cells were triggered for chondrogenesis and dur-
ing the very early onset of differentiation upregulation of inﬂam-
matory mediators COX-2 (and PGE2), iNOS (and NO production),
IL-6 and TNFα was detected (1-8 hours). This inﬂammatory-
response peak was preceded by NFκβ nuclear translocation at
30-60 minutes in differentiation, indicating that expression of these
inﬂammatory mediators might be regulated by NFκβ activation.
To investigate the role of NFκβ activation during early chondro-
genesis, NFκβ activation was stimulated by LPS or TNFα. Both
lead to upregulation of inﬂammatory mediators and was accom-
panied by upregulation of Sox9 at early time points and RunX2,
Collagen II and Collagen X late in differentiation. In contrast, inhi-
bition of nuclear translocation of NFκβ by TLCK, sulfasalazine or
parthenolide prevented the upregulation of inﬂammatory media-
tors at early time points in chondrogenesis. Importantly, inhibition
of NFκβ activation also lead to a concentration dependent inhibi-
tion of chondrogenic differentiation, strongly suggesting that NFκβ
activation is an essential step during early chondrogenesis.
To verify these results, hBMSCs were used as an independent sys-
tem for chondrogenic differentiation. In concert with our ﬁndings
in ATDC5 cells, early chondrogenesis of hBMSCs is also accom-
panied with a similar upregulation of inﬂammatory mediators like
COX-2 and chondrogenic transcription factor Sox9.
Conclusions:During the very early onset of chondrogenesis NFκβ
translocates to the nucleus and seems to regulate the expression
of inﬂammatory mediators and the essential chondrogenic tran-
scription factor Sox9. Stimulation of NFκβ lead to an upregulation
of inﬂammatory mediators and enhanced chondrogenic differen-
tiation, whereas inhibition of NFκβ nuclear translocation inhibited
chondrogenesis. Our results point to an essential role for NFκβ
and inﬂammatory mediators during the ﬁrst steps of chondroge-
nesis, which might regulate Sox9 and subsequent expression of
cartilage molecules.
Also, these data show that the effect of NFκβ activation on cartilage
might depend on the status of cartilage development and is
not solely associated with cartilage degeneration. Importantly,
our results might pave the way for alternative strategies in the
optimization of osteochondrogenic progenitor cell based cartilage
repair techniques.
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BONE AND CARTILAGE DEGRADATION ARE COUPLED
UNDER SOME PATHOLOGICAL AND PHYSIOLOGICAL
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Purpose: The pathogenesis of osteoarthritis involves both
changes in bone and cartilage. These processes might be coupled
under some instances. The aim of the present investigation was
to investigate bone and cartilage degradation correlations in os-
teoarthritis patients as a function of sex, BMI, Kellgren-Lawrence
score and diurnal variation.
Methods: The study was a phase-I, 2-week, placebo-controlled,
double-blind, double-dummy, randomized, gender-stratiﬁed study
including 73 subjects (37 postmenopausal women and 36 men),
aged 57-75 years. Patients had to have painful OA of at least
one knee with a Kellgren-Lawrence index score of I-III. Subjects
were allocated to one of three treatment arms: 0.6 mg, 0.8 mg
or placebo. Each treatment was given twice-daily for 14 days. For
evaluation of pharmacodynamics, blood samples were collected
immediately prior to dosing and at ½, 1, 2, 4, 6, and 8 hrs after
morning dose and, for the pre-dinner dose, immediately prior to
dosing, and at the intervals of ½, 1, 2, and 4 hrs post-dose.
Urine samples were collected pre-dose, 2, 4, 6, 8, 13, and 15
hours after morning dose. Study parameters were changes in the
bone resorption marker of CTX-I (serum C-terminal telopeptide
of collagen type I) and the cartilage degradation marker, CTX-II
(urine C-terminal telopeptide of collagen type II).
Results: A signiﬁcant difference (p=0.04) in CTX-I between men
and women, and a borderline signiﬁcant difference between men
and women in CTX-II (p=0.06) was found. At baseline, a corre-
lation between CTX-I and KL-score were not found. In contrast
CTX-II levels were signiﬁcantly correlated to increasing KL-score
in both men and women (P=0.007). BMI and CTX-I was nega-
tively correlated r = -0.40 (p=0.002), whereas CTX-II showed a
weak and non-signiﬁcant positive correlation with BMI, r = 0.25
(p=0.12). No correlation between CTX-I and CTX-II was found
before morning dosing at day 1 and 14. 4 hours after dosing, a
signiﬁcant correlation (r=0.71, p<0.001) between changes in CTX-
I and CTX-II was seen in the sCT group on both day 1 and 14,
whereas in the placebo group a weakly signiﬁcant correlation was
found on day 1 (r=0.49, p=0.02), but not day 14. CTX-I displayed
marked diurnal variation in which a more than 50% decrease was
seen as a response to intake of lunch in the placebo group. CTX-II
displayed lower levels of diurnal variation, indicating that CTX-II
levels also are postprandial regulated.
Conclusions: Bone and cartilage degradation may be coupled
processes. Understanding of the physiological and pathological
situations in which coupling and uncoupling are present may
aid in the identiﬁcation of treatment opportunities for osteoarthri-
tis. We speculate that identiﬁcation of physiological processes in
which both bone and cartilage turnover are attenuated may aid
in the identiﬁcation of new treatment opportunities for osteoarthri-
tis.
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Purpose: To evaluate the expression of 15-lipoxygenase (LOX)-1
and -2 in articular chondrocytes and to investigate the effects of
their metabolites, 13-HODE and 15-HETE, on IL-1-induced MMP-1
and -13 expression.
Methods: The expression of 15-LOX-1 and -2 was analyzed by
reverse transcriptase-polymerase chain reaction (RT-PCR) and
Western blotting in chondrocytes, and by immunohistochemistry in
cartilage. Chondrocytes were stimulated with IL-1 in the absence
or presence of 13-HODE and 15-HETE and the level of MMP-
1 and -13 protein and mRNA expression were evaluated by
immunoassay and real-time RT-PCR, respectively. The role of
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PPARγ was evaluated using transient transfection experiments
and the PPARγ antagonist GW9662.
Results: Articular chondrocytes express 15-LOX-1 and -2 at
the mRNA and protein levels. 13-HODE and 15-HETE dose-
dependently decreased IL-1-induced MMP-1 and -13 protein and
mRNA expression. This effect does not require de novo protein
synthesis. 13-HODE and 15-HETE activated endogenous PPARγ
and GW9662 prevented their suppressive effect on MMP-1 and -13
production, suggesting the involvement of PPARγ in these effects.
Conclusions: This study is the ﬁrst to demonstrate the expression
of 15-LOX-1 and -2 in articular chondrocytes. Their respective
metabolites, 13-HODE and 15-HETE, suppressed IL-1-induced
MMP-1 and -13 expression in a PPARγ dependent pathway. These
data suggest that 15-LOXs may have chondroprotective properties
by reducing MMP-1 and -13 expression.
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FGF/VEGF RECEPTOR-DEPENDENT,
INTEGRIN-INDEPENDENT PHOSPHORYLATION OF P38,
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Purpose: The mitogen activated protein kinases (MAPKs) are a
family of intracellular proteins that are involved in the regulation of
cellular activities and the control of many inﬂammatory and stress
responses. We have previously demonstrated Jun N-terminal ki-
nase 3 (JNK)-dependent increases in proteoglycan synthesis and
selective, partially integrin-dependent activation of JNK kinases in
human chondrocyte cell lines following cyclical mechanical stimu-
lation (MS). Vincent and colleagues have recently shown FGF-2
dependent activation of extracellularly regulated kinase (ERK) in
porcine bead cultures following mechanical loading and human ar-
ticular cartilage following cutting or loading. The aim of this study
was to examine the phosphorylation of MAPKs in normal and
osteoarthritic (OA) human articular chondrocytes (HAC) follow-
ing MS, and to determine whether MAPK activation was integrin
and/or receptor of FGF/VEGF dependent.
Methods: Articular cartilage was obtained from patients with OA
undergoing knee joint replacement and normal human articu-
lar cartilage postmortem. Cartilage was graded macroscopically
for OA. After enzymatic isolation, chondrocytes were cultured in
monolayer. The cells were mechanically stimulated at 0.33 Hz and
3700 μstrain in the absence or presence of the FGF/VEGF recep-
tor inhibitor PD173074, integrin blocking antibodies (P4C10 (β1),
JB1A (β1), BIIG2 (α5) and P1F6 (αvβ5)) and gadolinium. Proteins
were analysed by Western blotting.
Results: p38, ERK1/2 and JNK were identiﬁed in normal and
OA HAC. Phosphorylation of p38 increased in normal and OA
chondrocytes after 5 minutes MS and ERK1/2 phosphorylation
increased in normal chondrocytes following 10 minutes MS. Phos-
phorylation of ERK1/2 in OA HAC following MS was more variable.
Phosphorylation of 46 kDa JNK increased after 10 minutes MS,
but no phosphorylation of 54kDa JNK could be detected follow-
ing MS in normal or OA chondrocytes. In normal chondrocytes
MS-induced phosphorylation of p38 and ERK were inhibited by
PD173074 at concentrations 25 nM. In OA chondrocytes MS-
induced phosphorylation of ERK was also inhibited by 25 nM
PD173074, but MS-induced phosphorylation of p38 was only inhib-
ited by higher concentrations of PD173074 (>250 nM) suggesting
the possibility of inhibition of VEGF. No inhibition of MAPK phos-
phorylation induced by MS was observed following pre-incubation
with integrin blocking antibodies or gadolinium (10 μM).
Conclusions: Normal and OA HAC express MAPKs in primary
monolayer culture and p38, JNK and ERK 1/2 are phosphorylated
following cyclical MS. Activation of MAPKs in normal and OA HAC
in monolayer cell culture following MS is FGF/VEGF receptor-
dependent and not mediated by integrins or stretch activated ion
channels.
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Purpose: Transforming growth factor-β (TGF-β) is a multifunc-
tional growth factor that regulates cell proliferation, differentiation
and extracellular matrix (ECM) production. TGF-β plays a critical
role in maintaining cartilage homeostasis and abnormal TGF-β
activity has been implicated in degenerative joint diseases such
as osteoarthritis (OA). Despite this, the information available on
TGF-β receptors in human chondrocytes is limited. Endoglin is a
TGF-β co-receptor predominantly expressed in endothelial cells
that binds TGF-β1 and -β3 with high afﬁnity in the presence of the
TGF-β type II receptor. Our previous work has shown that endoglin
is expressed in human chondrocytes and forms heteromeric com-
plexes with the TGF-β type I and type II receptors. The purpose
of this study was to determine if endoglin expression is regulated
during subculture-induced dedifferentiation and whether endoglin
regulates TGF-β Smad-dependent signaling and ECM production
in human chondrocytes.
Methods: Human chondrocytes (C28/I2, tst/AC62 and primary ar-
ticular chondrocytes) were grown in alginate 3D culture to promote
chondrocyte redifferentation and then cultured in monolayer for 24
hours (early passage) or serially passaged up to 10 times (late
passage) to promote chondrocyte dedifferentiation. Early passage
chondrocytes were transfected with (i) endoglin or its empty vector,
(ii) endoglin-speciﬁc antisense morpholinos or control morpholinos
or (iii) endoglin-speciﬁc siRNA or control siRNA and treated without
or with TGF-β1 under serum-free conditions. Endoglin expression
was determined by afﬁnity labelling with 125TGF-β1, Western blot-
ting and RT-PCR. TGF-β responsiveness was determined by mea-
suring phosphorylation of Smad2 and ECM (type II collagen and
PAI-1) expression by Western blot. Smad3-driven transcriptional
activity was determined using the Smad3-responsive CAGA12-lux
luciferase reporter construct.
Results: Endoglin expression is increased and type II collagen ex-
pression is decreased in human chondrocytes during subculture-
induced dedifferentiation. Endoglin inhibits Smad2 phosphoryla-
tion, Smad3-driven transcriptional activity and ECM production in
reponse to TGF-β treatment.
Conclusions: Our results suggest that endoglin may represent
a potential marker of chondrocyte phenotype and establish a
link between endoglin expression, ECM production and TGF-β
responsiveness. Understanding mechanisms regulating endoglin
expression may lead to novel therapeutic approaches to promote
cartilage regeneration and repair to combat degenerative joint
diseases including OA.
